| Accession Number: | 0001839516-23-000002 |
| Date: | 2023-03-17 |
| Issuer: | TARSUS PHARMACEUTICALS, INC. (TARS) |
| Original Submission Date: |
WHITFIELD DIANNE C.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2023-03-17 | S | 316 | d | $13.28 | 12,556 | direct | ||
| COMMON STOCK | 2023-03-20 | S | 333 | d | $12.61 | 12,223 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | the sale reported on this form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the previously reported vesting and settlement of restricted stock units. the sale is mandated by the issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. |
